Mr. Shameze Rampertab reports

ZOMEDICA ANNOUNCES STOCK OPTION GRANT AND PENDING SHARE ISSUANCES

Zomedica Pharmaceuticals Corp. has granted an aggregate of 535,000 options to acquire common shares of the company to an officer and to an employee of the company, each such option being exercisable at a price of $1.50 per common share for a two-year term expiring on Feb. 24, 2019. The stock options have all vested immediately upon the date of grant. The stock options, and any common shares issued upon exercise of the stock options, are subject to a four-month hold period expiring on June 25, 2017.

The company further announces that it has entered into an agreement to settle an amount of $50,000 (U.S.) (approximately $65,420) through the issuance of an aggregate of 43,613 common shares of the company at a price of $1.50 per share. The foregoing shares-for-debt transaction is subject to approval by the TSX Venture Exchange. In addition, Zomedica also advises that its previously announced non-brokered private placement offering of 6,657,520 common shares at a price of $1.50 per common share is continuing. The first tranche of this offering was completed on Dec. 29, 2016, with an aggregate of 791,373 common shares having been issued for aggregate gross proceeds of $1,187,059.50. All of the foregoing shares will, upon issuance, be subject to a statutory four-month hold period in accordance with applicable securities laws.

About Zomedica Pharmaceuticals Corp.

Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

We seek Safe Harbor.